Interim Chief Medical Officer
chief medical officer
Dr. Hirmand was appointed interim chief medical officer in October 2015. Dr. Hirmand joined Medivation in 2007 as senior director of clinical development, was promoted to vice president of clinical development in 2008, and promoted to senior vice president of clinical development and operations in September 2014. Before joining Medivation, he was a senior director of clinical development at Nuvelo, Inc. (now ARCA biopharma), where he led the clinical development department comprised of clinical operations, clinical data management and clinical sciences/medical monitor staff. Before that, he served as director of oncology development at SuperGen, Inc. (now Astex Pharmaceuticals, Inc) and as associate director of clinical research at Amgen, Inc. (formerly Tularik, Inc.), where he led clinical development efforts for Tularik's oncology trials. Early in his career, he was a clinical scientist and manager of market development and product evaluation at Theravance Biopharma, Inc. Dr. Hirmand holds a Bachelor of Arts degree from Cornell University. Dr. Hirmand received his M.D. from Harvard Medical School.